GlaxoSmithKline says Q3 net profits drop 18.5%

British drugmaker GlaxoSmithKline said Wednesday that third-quarter net profits fell 18.5 percent from a year earlier to £1.12 billion ($1.80 billion, 1.39 billion euros), hit by weak conditions in Europe.

Earnings after taxation in the group's third quarter, or three months to the end of September, compared with £1.378 billion in the same part of the previous year, GSK said in a results statement.

Revenues fell five percent to £6.527 billion in the reporting period, hit by a steeper 9.0-percent decline in Europe.

"We continue to make progress on our strategy, particularly through increasing our sales exposure to growth businesses, notably , and delivering a step-change in output from research and development," GSK chief executive Andrew Witty added in the earnings release.

"As expected, reported sales performance this quarter of minus 5.0 percent was impacted by demanding prior-year comparisons, product disposals and continuing weakness in the European environment for pharmaceuticals and vaccines."

add to favorites email to friend print save as pdf

Related Stories

GlaxoSmithKline profits up on lower tax

Jul 25, 2012

British drugmaker GlaxoSmithKline on Wednesday said its second quarter net profit rose 13.3 percent from a year earlier to £1.25 billion ($1.94 billion, 1.59 billion euros).

GlaxoSmithKline says net profits drop 13% in Q1

Apr 25, 2012

British drugsmaker GlaxoSmithKline said Wednesday that its net profits dropped 13 percent to £1.325 billion (1.616 billion euros, $2.134 billion) in the first quarter from a year earlier.

GlaxoSmithKline posts rising Q3 profits

Oct 26, 2011

British drugmaker GlaxoSmithKline said Wednesday that third-quarter net profit rose seven percent, boosted by growth across its main pharmaceuticals, vaccines and consumer healthcare divisions.

Recommended for you

Amgen misses 1Q views as higher costs cut profit

Apr 22, 2014

Despite higher sales, biotech drugmaker Amgen's first-quarter profit fell 25 percent as production and research costs rose sharply, while the year-ago quarter enjoyed a tax benefit. The company badly missed ...

Valeant, Ackman make $45.6B Allergan bid

Apr 22, 2014

Valeant Pharmaceuticals and activist investor Bill Ackman have unveiled details of their offer to buy Botox maker Allergan, proposing a cash-and-stock deal that could be worth about $45.6 billion.

User comments